{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=79",
    "query": {
      "intervention": "SC",
      "page": 79
    },
    "page_size": 10
  },
  "pagination": {
    "page": 79,
    "page_size": 10,
    "total_count": 3868,
    "total_pages": 387,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=80&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=78&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T19:46:31.657Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07822373",
      "title": "A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle-invasive Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enfortumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-11",
      "completion_date": "2035-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07822373"
    },
    {
      "nct_id": "NCT03273842",
      "title": "A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PF-06881894",
          "type": "BIOLOGICAL"
        },
        {
          "name": "US-approved Neulasta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 422,
      "start_date": "2017-10-27",
      "completion_date": "2018-07-25",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 4,
      "location_summary": "Coral Gables, Florida • Jacksonville, Florida • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03273842"
    },
    {
      "nct_id": "NCT07225686",
      "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Maridebart cafraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 250,
      "start_date": "2025-12-19",
      "completion_date": "2028-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 13,
      "location_summary": "Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225686"
    },
    {
      "nct_id": "NCT00771667",
      "title": "A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 1mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 3 mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 6 mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV - Responder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Responder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Nonresponder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 526,
      "start_date": "2008-12",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-04-01",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 88,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00771667"
    },
    {
      "nct_id": "NCT01283971",
      "title": "A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tocilizumab [RoActemra/Actemra]",
          "type": "DRUG"
        },
        {
          "name": "adalimumab",
          "type": "DRUG"
        },
        {
          "name": "placebo to tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "placebo to adalimumab",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "folate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2011-05",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-10",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 107,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283971"
    },
    {
      "nct_id": "NCT01057667",
      "title": "A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "RO5024048",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin [Copegus]",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 168,
      "start_date": "2010-02",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01057667"
    },
    {
      "nct_id": "NCT02007434",
      "title": "Patient Experience Study of Deoxycholic Acid Injection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate or Severe Submental Fullness"
      ],
      "interventions": [
        {
          "name": "Deoxycholic Acid Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cold Compress",
          "type": "OTHER"
        },
        {
          "name": "Lidocaine / Epinephrine",
          "type": "DRUG"
        },
        {
          "name": "Loratadine",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Compression Chin Strap",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kythera Biopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2013-12",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2015-07-28",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02007434"
    },
    {
      "nct_id": "NCT01695330",
      "title": "Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Subcutaneous bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-05",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-16",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 1,
      "location_summary": "West Hollywood, California",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01695330"
    },
    {
      "nct_id": "NCT01267812",
      "title": "Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Contiguous Stage II Mantle Cell Lymphoma",
        "Noncontiguous Stage II Mantle Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Stage I Mantle Cell Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage IV Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "RNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-10-03",
      "completion_date": "2020-11-02",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Seattle, Washington",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01267812"
    },
    {
      "nct_id": "NCT06651281",
      "title": "Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease",
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Tulisokibart",
          "type": "DRUG"
        },
        {
          "name": "Placebo to tulisokibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1380,
      "start_date": "2024-11-25",
      "completion_date": "2037-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-07T19:46:31.657Z",
      "location_count": 12,
      "location_summary": "Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more",
      "locations": [
        {
          "city": "Bristol",
          "state": "Connecticut"
        },
        {
          "city": "Ypsilanti",
          "state": "Michigan"
        },
        {
          "city": "Liberty",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Garland",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06651281"
    }
  ]
}